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Amyloid β peptide (Aβ) is a key player in the development of Alzheimer’s disease
(AD). It is the primary component of senile plaques in AD patients and is also found
in soluble forms. Cholinergic activity mediated by α7 nicotinic receptors has been
shown to be affected by Aβ soluble forms. To shed light into the molecular mechanism
of this effect, we explored the direct actions of oligomeric Aβ1–40 and Aβ1–42 on
human α7 by fluorescence spectroscopy and single-channel recordings. Fluorescence
measurements using the conformational sensitive probe crystal violet (CrV) revealed that
in the presence of Aβ α7 undergoes concentration-dependent conformational changes.
Exposure of α7 to 100 pM Aβ changes CrV KD towards that of the desensitized
state. However, α7 is still reactive to high carbamylcholine (Carb) concentrations.
These observations are compatible with the induction of active/desensitized states
as well as of a novel conformational state in the presence of both Aβ and Carb.
At 100 nM Aβ, α7 adopts a resting-state-like structure which does not respond to
Carb, suggesting stabilization of α7 in a blocked state. In real time, we found that
Aβ is capable of eliciting α7 channel activity either in the absence or presence of the
positive allosteric modulator (PAM) PNU-120596. Activation by Aβ is favored at picomolar
or low nanomolar concentrations and is not detected at micromolar concentrations.
At high Aβ concentrations, the mean duration of activation episodes elicited by
ACh in the presence of PNU-120596 is significantly reduced, an effect compatible
with slow open-channel block. We conclude that Aβ directly affects α7 function
by acting as an agonist and a negative modulator. Whereas the capability of low
concentrations of Aβ to activate α7 could be beneficial, the reduced α7 activity in
the presence of higher Aβ concentrations or its long exposure may contribute to the
cholinergic signaling deficit and may be involved in the initiation and development
of AD.
Keywords: nicotinic receptor, patch-clamp recordings, single-channel currents, Cys-loop receptor, amyloid
peptide, crystal violet
Abbreviations: ACh, acetylcholine; Carb, carbamylcholine; Aβ1–42, amyloid-β1–42 peptide; Aβ1–40, amyloid-β1–40 peptide;
nAChR, nicotinic acetylcholine receptor; CrV, crystal violet; NS-1738, N-(5-Chloro-2-hydroxyphenyl)-N′-[2-chloro-5-
(trifluoromethyl) phenyl]urea; PNU-120596, [N-(5-Chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea].
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease characterized by loss of memory, multiple cognitive
impairments and changes in personality and behavior. Memory
impairment in AD is associated with neuronal degeneration
as well as synaptic damage. Although AD is a multifactorial
disease, accumulation of amyloid-β peptides (Aβ) is one of the
major pathological factors. Accumulation phase starts with low
molecular weight fractions of Aβ (monomers, dimers, or trimers)
and continues with larger oligomers or insoluble amyloid fibrils
(Sadigh-Eteghad et al., 2014). Although plaques remain the
principal identifiers and predictors of Alzheimer’s disease, a clear
paradigm shift has occurred that emphasizes the primacy of Aβ
oligomers in disease causation (Lacor et al., 2004; Shankar et al.,
2008; Hayden and Teplow, 2013; Collins-Praino et al., 2014).
Despite all research efforts, there are still many unsolved aspects
regarding the molecular mechanisms underlying Aβ pathogenic
actions. One of these mechanisms involves the interaction of
Aβ with synaptic receptors, which consequently emerge as novel
druggable sites to restore cognitive functions in AD patients
(Kandimalla and Reddy, 2017).
Cholinergic neurons with a pivotal role in learning and
memory are mainly involved in the pathogenesis of AD. Indeed,
inhibitors of acetylcholinesterase (AChE), which by decreasing
ACh breakdown enhance cholinergic neurotransmission, are to
date one of the main specific therapeutic drugs, although their
efficacy is limited (Kandimalla and Reddy, 2017).
The α7 nicotinic acetylcholine receptor (nAChR) has been
shown to be associated with AD. α7 is highly expressed in
hippocampus, cortex and several subcortical limbic regions
and is involved in cognition, sensory processing information,
attention, workingmemory, and reward pathways (Lendvai et al.,
2013). Reduction of α7 in brain, particularly in the hippocampus,
has been reported in AD patients (Buckingham et al., 2009;
Dineley et al., 2015).
α7 is a pentameric ligand-gated ion channel that responds
to ACh by opening an intrinsic channel permeable to cations
that triggers rapid membrane depolarization and calcium influx
(Wonnacott, 2014). However, α7 also acts as a metabotropic
receptor and triggers several signal transduction pathways as well
as the release of calcium from intracellular stores (Kabbani et al.,
2013; Egea et al., 2015; Guan et al., 2015; Corradi and Bouzat,
2016; Bouzat et al., 2018). This metabotropic activity has been
associated to synaptic plasticity and neuroprotection, including
against Aβ damage (Buckingham et al., 2009; Inestrosa et al.,
2013; Jin et al., 2015).
Enhancement of α7 activity is emerging as a therapeutic
strategy for cognitive impairment in AD. Positive allosteric
modulators (PAMs) are the most promising therapeutic
compounds because they maintain the temporal and spatial
characteristics of endogenous activation, are more selective than
agonists, and reduce tolerance due to desensitization (Chatzidaki
and Millar, 2015; Terry et al., 2015; Corradi and Bouzat, 2016;
Echeverria et al., 2016; Yang et al., 2017; Bouzat et al., 2018).
Based on their effects on macroscopic currents, PAMs have been
classified as type I PAMs, that mainly enhance agonist-induced
peak currents, and type II PAMs, that enhance agonist-elicited
currents and also decrease desensitization and recover receptors
from desensitized states (Bertrand and Gopalakrishnan, 2007;
Grønlien et al., 2007; Andersen et al., 2016).
Both α7 agonist- and antagonist-like actions of Aβ have
been described in different cells and tissues (Wu et al., 2004;
Khan et al., 2010; Li et al., 2011; Parri et al., 2011; Sadigh-
Eteghad et al., 2014; Liu et al., 2015; Yan et al., 2015).
Studies have been focused mainly on evaluation of the effects
of Aβ on α7 metabotropic activity, which includes signaling
pathways, such as ERK/MAPK, PI3K/AKT, JAK-2/STAT-3 and
intracellular calcium mobilization. The acute effects of Aβ on
α7 electrical activity have been explored at the macroscopic
current level. Despite problems of comparability and some
dissimilar results, probably due to variations on the aggregation
state and concentration of amyloid peptides (see Buckingham
et al., 2009), the consensus indicates that low concentrations of
Aβ (picomolar) activate α7 whereas higher concentrations lead
to current inhibition (Liu et al., 2001; Dineley et al., 2002; Grassi
et al., 2003; Pym et al., 2005; Parri et al., 2011).
To shed light into the molecular mechanism of the direct
action of Aβ on α7, we expressed human α7 on mammalian cells
and evaluated functional effects by fluorescence spectroscopic
measurements and electrophysiological recordings. We used Aβ
preparations enriched in oligomeric forms since these species
were shown to be involved in cognitive impairment, inhibition
of long-term potentiation, memory loss and α7 modulation
(Walsh et al., 2002; Wang et al., 2002; Cleary et al., 2005;
Parri et al., 2011). By taking advantage of the potential of
single-channel recordings in providing information unattainable
by macroscopic measurements, we deciphered the direct
molecular effects of oligomeric Aβ as activator and inhibitor
of α7 channels. By using a fluorescent conformational probe,
we revealed that Aβ elicits different concentration-dependent




Acetylcholine (ACh) and human amyloid-β1–42 (Aβ1–42)
were purchased from Sigma-Aldrich (St. Louis, MO, USA);
NS-1738 N-(5-Chloro-2-hydroxyphenyl)-N′-[2-chloro-5-
(trifluoromethyl) phenyl]urea, PNU-120596 [N-(5-Chloro-2,4-
dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea] and rat
amyloid-β1–40 (Aβ1–40) were obtained from Tocris Biosciences
(Bristol, UK).
Receptor Expression
BOSC-23 cells, derived from HEK 293 cells (Pear et al.,
1993), were transfected by calcium phosphate procedure with
human α7 cDNA subcloned in pRBG4 vector (Bouzat et al.,
1994). Plasmids harboring cDNAs of the α7 chaperone proteins
Ric-3 and NACHO were incorporated to favor α7 expression
(Bouzat et al., 2008; Andersen et al., 2016; Nielsen et al.,
2018). All transfections were carried out for about 12–18 h
in Dulbecco’s Modified Eagle Medium (DMEM) with 10%
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fetal bovine serum and terminated by exchanging the medium.
Cells were used for single-channel recordings 2–4 days after
transfection. To facilitate identification of transfected cells,
a separate plasmid encoding green fluorescent protein was
included in all transfections.
Amyloid-β Peptide Preparations
Aβ1–40 or Aβ1–42 were resuspended in dimethyl sulfoxide at a
concentration of 10 mg/ml (peptide stock solution) and stored
in aliquots at −80◦C. Aβ oligomers were prepared immediately
prior to use according to previously published methods (Uranga
et al., 2016; Pascual et al., 2017). Briefly, aliquots of peptide stock
(10 µl) were added to 280 µl of phosphate buffered saline (PBS;
pH 7.4) and stirred continuously (300 rpm) for 120 min and
stored at 4◦C until use.
Transmission electron microscopy (TEM) studies were
carried out according to previously published methods with
slight modifications (Uranga et al., 2016; Pascual et al.,
2017). Briefly, 10 µl media containing the peptide was
placed on a carbon-coated grid and incubated for 60 s.
Ten microliters of 0.5% glutaraldehyde was added to the
grid followed by incubation for an additional 60 s. The
grid was then washed with drops of water and dried.
Finally, the grid was stained for 2 min with 2% uranyl
acetate and air dried. The grid was subsequently examined
under a Jeol 100 Cx II electron microscope (Uranga et al.,
2016). TEM photomicrographs showed that Aβ preparations
included spheroidal structures individually or in small groups
(Supplementary Figure S1). These ultrastructural forms were
compatible with a heterogeneous array of oligomers, thus
discarding the presence of fibrils (Uranga et al., 2016; Pascual
et al., 2017).
Single-Channel Recordings
Single-channel recordings were obtained in the cell-attached
patch configuration. The bath and pipette solutions contained
142 mM KCl, 5.4 mM NaCl, 1.8 mM CaCl2, 1.7 mM MgCl2 and
10 mM HEPES (pH 7.4). For potentiation, 1 µM PNU-120596
or 10 µM NS-1738 were added to the pipette solution together
with ACh.
Single-channel currents were digitized at 5–10 µs intervals,
low-pass filtered at a cut-off frequency of 10 kHz using an
Axopatch 200B patch-clamp amplifier (Molecular Devices Corp.,
CA, USA). Single-channel events were idealized by the half
amplitude threshold criterion using the program QuB 2.0.0.28
(Qin et al., 1996, 1997; State University of New York at Buffalo)
with a digital low-pass filter at 9 kHz. A filter of 3 kHz was
used in recordings with PNU-120596 to facilitate the analysis.
The open and closed time histograms obtained from idealization
were fitted by the maximum interval likelihood (MIL) function
in QuB (Qin et al., 1996, 1997), with a dead time of 0.1 ms. This
analysis was performed by sequentially adding an open and/or
closed state to a starting C ↔ O model in order to properly
fit the corresponding histograms (Fabiani et al., 2018; Lasala
et al., 2018). Final models contained five-six closed states and
three-four open states for α7 in the presence of ACh plus PNU-
120596, five-six closed states and three open states for α7 in
the presence of ACh plus NS-1738, or three closed states and
one-two open states for α7 in the presence of ACh and absence
of PAMs.
Clusters were identified as a series of closely separated
openings preceded and followed by closings longer than a critical
duration. Different critical closed times were calculated by MIL
between each closed component. Critical times between the
third and fourth closed components for α7 in the presence
of PNU-120596 (∼30–60 ms) or NS-1738 (∼2–8 ms) were
selected in QuB to chop the idealized data and create a
sub-data set that only contained clusters to define mean cluster
duration.
Fluorimetric Measurements
Fluorimetric measurements were performed in a SLM model
4800 fluorimeter (SLM Instruments, Urbana, IL, USA) using
a vertically polarized light beam from an Hannovia 200-W
mercury/xenon arc obtained with a Glan-Thompson polarizer
(4 nm excitation and emission slits).
Crystal violet (CrV) was used as a probe to detect
conformational changes (Lurtz and Pedersen, 1999; Sun et al.,
2017; Fabiani et al., 2018). nAChR-rich membranes were
prepared from Torpedo californica electric tissue as described
previously (Fernández Nievas et al., 2008; Perillo et al.,
2012; Fabiani et al., 2018). CrV experiments using Torpedo
membranes or α7-expressing cells were conducted as described
previously for the Torpedo nAChR (Fernández Nievas et al.,
2008; Perillo et al., 2012; Fabiani et al., 2018). Torpedo
membranes or BOSC-23 cells expressing α7 were resuspended
on phosphate saline buffer with a protein concentration
of 100 µg/ml or up to an absorbance value of ∼0.5 at
280 nM measured on a Jasco V-630 spectrophotometer (JASCO
Deutschland GmbH), respectively. The suspended cells or
membranes were incubated with Aβ oligomers for 20 min.
For measurements conducted in the desensitized state, the
membrane or cell suspensions were additionally incubated
for 15 min with 1 mM or 20 mM carbamylcholine (Carb),
respectively. The suspensions were subsequently titrated with
increasing concentrations of CrV (in water). After each addition
of CrV, the samples were incubated for 15 min before
obtaining the fluorescence emission spectra. CrV was excited at
600 nm, and the fluorescence emission spectra were collected
from 605 to 700 nm. Before the first addition of CrV,
a background fluorescence emission spectrum was obtained
for each sample. The spectrum was then subtracted from
the emission spectra obtained in the presence of CrV and
the maximum intensity (at 623–625 nm) was measured. To
determine the CrV dissociation constant (KD), the value of
the CrV maximum fluorescence emission was plotted as a
function of the logarithmic CrV concentration (M). The resulting
sigmoid curve was fitted by the Boltzmann function and the
KD was calculated using the program Origin 7.0 (OriginLab
Corporation).
Statistical Analysis
Intergroup comparisons were carried out using one-way
analyses of variance (ANOVA), Dunnett’s multiple comparisons
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test (Graphpad PRISM software). The values represent the
average ± SD of the total number of samples indicated.
Statistically significance difference was established at
p-values<0.05.
RESULTS
Amyloid β Oligomers Induce
Conformational Changes in α7
To examine the potential of oligomeric Aβ peptides to directly
affect α7, we first used the conformational-sensitive probe CrV
and measured its affinity for the receptor before and after
exposure to Aβ by fluorescence spectroscopy.
CrV has been extensively used for studies in the Torpedo
muscle nAChR where it shows low affinity for the resting state
(KD values∼400 nM, Fernández Nievas et al., 2008; Perillo et al.,
2012) and high affinity for the desensitized state (KD values
∼60 nM; Fernández Nievas et al., 2008; Perillo et al., 2012;
Fabiani et al., 2018; Figure 1A).
We first determined if CrV can be used as a conformational
probe for the human α7 receptor. Suspensions of BOSC-23 cells
expressing α7 were titrated with increasing concentrations of
CrV. Saturable CrV binding yielded a KD value of 492 ± 41 nM
for resting α7 receptors, indicating an affinity similar to that
for the muscle nAChR in the resting state. Interestingly,
measurements in the desensitized state, which was induced
by 20-min preincubation with Carb, yielded a KD value of
680 ± 89 nM for CrV binding (Figures 1A,B). The maximal
fluorescence intensities of the samples were similar at resting and
desensitized conditions, thus discarding that the lower affinity
for the desensitized state corresponds to reduced binding of the
probe in the latter state. These results indicate that CrV saturates
its binding sites at both conditions with different affinities. Thus,
opposite to its binding affinity profile for the muscle nAChR,
CrV shows higher affinity for resting than for desensitized states
in α7.
We next determined the effects of low (0.1 nM) and
high (100 nM) Aβ1–40 concentrations on α7 conformation by
measuring CrV KD values to resting and desensitized states
(Figure 1B).
Exposure of α7 in the resting state (in the absence of
Carb) to 0.1 nM Aβ1–40 increased the CrV KD towards that of
the desensitized state, indicating that amyloid peptides induce
conformational changes in α7. Interestingly, subsequent addition
of Carb induced a further displacement to higher KD values,
suggesting that the agonist can lead to further conformational
changes (Figure 1B). KD values for desensitized conditions were
statistically significantly different in the absence and presence
of Aβ (Figure 1B). Similar results were obtained with 0.1 nM
Aβ1–42.
On the other hand, incubation of resting α7 receptors with
1,000-fold higher Aβ1–40 concentration (100 nM) did not induce
statistically significant changes in the CrV KD value (Figure 1B).
Furthermore, the KD value remained constant even after addition
of 20 mMCarb, indicating that α7 was not reactive to the agonist.
Similar results were obtained with high (100 nM) Aβ1–42.
FIGURE 1 | α7 conformational changes depend on Amyloid β peptide (Aβ)
concentrations. (A) Crystal violet (CrV) titration curves obtained with muscle
nicotinic acetylcholine receptor (nAChR) from T. californica rich membranes
(circles) and with human α7 (squares) in the absence (gray, Resting) and
presence of carbamylcholine (Carb; red, desensitized). The arrows indicate
the changes from resting to desensitized conditions for each nAChR type.
(B) Changes in KD values of CrV by the exposure to low (0.1 nM) and high
(100 nM) concentrations of Aβ1–40. KD values of CrV were calculated from the
titration curves, in the absence and presence of 20 mM Carb (gray and red
columns, respectively). Each column corresponds to the average ± SD of
more than four independent experiments. Statistically significant differences
are shown by asterisks, ∗p < 0.05.
Oligomeric Amyloid-β Peptides at Low
Concentrations Trigger Human α7 Channel
Opening
Once established that oligomeric Aβ peptides induce
conformational changes that are sensitive to concentration,
we took advantage of the potential of single-channel recordings
to reveal the mechanistic basis of this modulation.
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 February 2019 | Volume 13 | Article 37
Lasala et al. Aβ Action at α7 Channel
FIGURE 2 | Single-channel activity elicited by Aβ. Single-channel recordings
were performed in the cell-attached patch configuration at −70 mV
membrane potential. Representative α7 single-channel traces from a
continuous recording in the presence of 100 µM acetylcholine (ACh) or
100 pM Aβ1–40. For each condition, a trace at higher temporal resolution is
shown (bottom traces). Channel openings are shown as upward deflections.
Filter: 9 kHz.
To first determine if Aβ can activate human α7, we examined
single-channel activity from BOSC-23 cells expressing the
receptor (Figure 2). In the presence of 100 µM ACh, α7 exhibits
single brief openings flanked by long closings, or less often,
several openings in quick succession, which are called bursts
(Bouzat et al., 2008; Andersen et al., 2016). The mean open
duration was 0.36 ± 0.07 ms (n = 3) and the mean burst
duration was 0.77 ± 0.21 ms (n = 3; Figure 2). No α7 channel
activity was detected in the absence of agonist. However, 100 pM
Aβ1–40 elicited the typical α7 channel openings (Figure 2). The
number of active patches was lower than in the presence of
ACh (28% transfected cells showed channel activity). Channel
activity was not detected if Aβ1–40 was increased to 10 nM and
100 nM (n = 16 patches of different cells and transfections),
indicating that activation is favored at low concentrations. These
experiments were performed in parallel with recordings with
ACh as the agonist to discard that the lack of channel activity
was due to the lack of functional expression.
We next performed recordings in the presence of the type II
PAM PNU-120596, which increases the probability of agonist-
elicited channel opening and, consequently, favors the detection
of infrequent opening events (daCosta et al., 2011; Andersen
et al., 2016). By itself, PNU-120596 cannot elicit channel
activation (Hurst et al., 2005). In the presence of 1 µM PNU-
120596, α7 channel activity elicited by ACh (100 µM) appears in
long activation periods of high frequency, named clusters, whose
mean duration is about 1–3 s (Figure 3, Table 1; Andersen et al.,
2016).
In the absence of ACh, Aβ1–40 or Aβ1–42 at a low
concentration (100 pM) elicited clusters of PNU-120596-
potentiated α7 channels (Figure 3). Again, the proportion
of active patches was lower than in the presence of ACh.
Whereas almost all patches (>90%) showed channel activity
with ACh, the percentage of active patches was reduced in the
presence of Aβ1–40 or Aβ1–42 as agonists (Table 1). Moreover,
as Aβ concentration increased, the number of patches showing
α7 activity decreased. As shown in Table 1, at 100 pM 43% and
78% of the patches showed clusters elicited by Aβ1–40 or Aβ1–42,
respectively, but no channel activity was detected at 100 nM.
Thus, also in the presence of a PAM, activation by Aβ is favored
at picomolar or low nanomolar concentrations.
Although the frequency of clusters is usually variable among
patches from different cell transfections, it was systematically
lower in the presence of Aβ with respect to ACh as illustrated
in typical recordings shown in Figure 3. For a better comparison,
recordings with ACh or Aβ were performed in the same batch of
transfected cells.
In the presence of ACh and PNU-120596, each cluster is
composed of two or three bursts that contain long-duration
openings separated by brief closings (daCosta et al., 2011;
Andersen et al., 2016). Clusters elicited by Aβ in the presence
of PNU-120596 showed the typical architecture observed
with ACh (Figure 3). The analysis showed no statistically
significant differences in the mean cluster duration at all tested
TABLE 1 | Activation of α7 by Amyloid β peptide (Aβ) in the presence of
N-(5-Chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea (PNU)-120596.




100 No 0 100 (6) 2263 ± 990
0 Aβ1–40 0.1 42.9 (7) 762 ± 316
0 1 22.2 (18) 2016 ± 1364
0 10 30.0 (10) 5229 ± 1392∗
0 100 0 (9) Nd
0 Aβ1–42 0.1 77.8 (9) 1401 ± 805
0 1 46.2 (13) 1208 ± 946
0 10 33.3 (9) 1751 ± 766
0 100 0 (6) Nd
Single-channel currents from cells expressing human α7 were recorded in the presence
of 1 µM PNU-120596 plus 100 µM acetylcholine (ACh) or Aβ at the indicated
concentrations. The mean cluster duration was obtained from the corresponding
histograms. Nd: not detected. Statistical comparisons were performed against the
corresponding control condition using analyses of variance (ANOVA; Dunnett’s multiple
comparisons test). ∗p < 0.05.
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FIGURE 3 | Single-channel activity elicited by Aβ in the presence of
N-(5-Chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea
(PNU-120596). Single-channel recordings were performed in the
cell-attached patch configuration at −70 mV membrane potential.
Representative α7 single-channel traces from a continuous recording in the
presence of the type II positive allosteric modulator (PAM) PNU-120596
(1 µM) together with 100 µM ACh, 100 pM Aβ1–40 or 100 pM Aβ1–42.
Channel openings are shown as upward deflections.
concentrations, except for 10 nM Aβ1–40 at which clusters were
slightly prolonged (Table 1).
The results confirm that Aβ at picomolar and low nanomolar
concentrations can trigger activation of α7 channels.
Amyloid-β Peptides Decrease the Duration
of α7 Activation Episodes
We next explored the effect of Aβ on ACh-elicited channels. To
this end, we recorded channels activated by 100 µM ACh in
the presence of Aβ1–42 (10 and 100 nM). The mean durations
of openings and bursts at both Aβ concentrations were slightly
briefer than the control but the differences were not statistically
significant (Table 2). Due to the very brief durations, differences
on these values may be inaccurate since they approach the
resolution limit of our system. We therefore tested the effect of
Aβ (10–1,000 nM) on ACh-activated channels in the presence
TABLE 2 | Effect of Aβ on ACh-elicited channel activity.





No No 0 3 0.36 ± 0.07 0.77 ± 0.21
Aβ1–42 10 3 0.26 ± 0.02 0.48 ± 0.06
100 3 0.27 ± 0.04 0.49 ± 0.11
PNU-120596 No 0 6 159.6 ± 69.6 2263 ± 990
Aβ1–40 50 3 176.7 ± 22.5 2220 ± 256
100 5 61.6 ± 33.1∗ 698 ± 409∗
1, 000 3 23.4 ± 22.0∗ 931 ± 303∗
Aβ1–42 10 5 61.1 ± 23.8∗ 888 ± 261∗
100 5 54.7 ± 47.8∗ 755 ± 560∗
1, 000 6 59.6 ± 32.2∗ 883 ± 289∗
NS-1738 No 0 12 4.2 ± 1.8 31.1 ± 8.8
Aβ1–40 100 10 2.7 ± 1.1∗ 8.4 ± 4.8∗∗∗∗
Aβ1–42 100 4 2.1 ± 1.0∗ 10.7 ± 2.4∗∗∗∗
Single-channel recordings from cells expressing human α7 were recorded in the
presence of 100 µM ACh, 100 µM ACh plus 1 µM PNU-120596 or 100 µM ACh plus
10 µM N-(5-Chloro-2-hydroxyphenyl)-N′-[2-chloro-5-(trifluoromethyl) phenyl]urea (NS-
1738). The effects of Aβ was evaluated for all conditions. The mean open and cluster
durations were obtained from the corresponding histograms. Statistical comparisons
were performed against the corresponding control condition using ANOVA (Dunnett’s
multiple comparisons test). ∗p < 0.05, ∗∗∗∗p < 0.0001.
1 µM PNU-120596, which by increasing the duration of the
activation episodes allows a better description of the molecular
effects.
The presence of Aβ1–40 or Aβ1–42 reduced the mean duration
of openings and clusters elicited by ACh and potentiated
by PNU-120596 as a function of concentration (Figure 4A).
Whereas 50 nMAβ1–40 did not affect open and cluster durations,
10 nM Aβ1–42 reduced these durations. The mean open and
cluster durations were statistically significantly briefer than the
control at concentrations equal and higher than 100 nM for
Aβ1–40 and 10 nM for Aβ1–42 (p < 0.05, Table 2). At these
concentrations, the mean durations were reduced about 3-fold
(Figure 4B).
To further determine if the effect of Aβ on α7 potentiation is
specific for type II PAMs, we evaluated the action on channels
activated by ACh and potentiated by NS-1738, which is a type
I PAM (Timmermann et al., 2007; Andersen et al., 2016). In
the presence of ACh, NS-1738 (10 µM) increased the mean
open duration from about 0.3 ms to about 4 ms and opening
events appeared grouped in bursts of about 30 ms (Figure 5,
Table 2). In the presence of 100 nM Aβ1–40 or Aβ1–42, the mean
burst duration was reduced to about 3-fold and the mean open
duration was also statistically significantly briefer than in the
control condition (Figure 5, Table 2).
Thus, we conclude that episodes elicited by ACh and
potentiated by both types of PAMs are reduced by Aβ at high
nanomolar concentrations.
DISCUSSION
Low concentrations (picomolar) of soluble Aβ peptides in the
brain of healthy people have been reported to play physiological
roles whereas in AD patients concentrations increase to the
nanomole range and trigger the formation of insoluble plaques,
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FIGURE 4 | Aβ decreases the duration of activation episodes elicited by
ACh and potentiated by PNU-120596. Single-channel recordings were
performed in the cell-attached patch configuration at −70 mV membrane
potential with 100 µM ACh and 1 µM PNU-120596 and in the absence or
presence of Aβ. (A) Representative clusters are shown for each condition.
Channels are shown as upward deflections. (B) Decrease of mean open and
cluster durations by Aβ. Each value corresponds to the mean ± SD of
different recordings. The number of recordings for each condition is shown in
the bars. The cluster and open durations for each recording were obtained
from the corresponding histograms and correspond to the slowest open
components ∗p < 0.05.
a major neuropathologic hallmark of AD (Dineley, 2007; Parihar
and Brewer, 2010; Collins-Praino et al., 2014; Puzzo et al., 2015).
However, the possibility that Aβ oligomers play an important
role in AD progression has gained weight (Miñano-Molina et al.,
2011; Puzzo et al., 2015). Moreover, in the absence of plaques,
intraneuronal accumulation of Aβ peptide has been shown
to correlate with the initial steps in the tau-phosphorylation
cascade, alterations in ERK2 signaling and impairment of higher
CNS functions in rats (Echeverria et al., 2004a,b). Another
feature of AD is the severe cholinergic deficit, which involves
mainly α4β2 and α7 receptors. It has been established that
α7 exhibits an exceptionally high Aβ affinity, an interaction
that may influence synaptic transmission and plasticity and
may also contribute to Aβ-mediated synaptic neural network
dysfunction and to the severe cholinergic deficit (Wang et al.,
2000; Buckingham et al., 2009; Puzzo et al., 2011; Dineley et al.,
2015). Several reports have described the intracellular pathways
FIGURE 5 | Aβ decreases the duration of events elicited by ACh and
potentiated by the type I PAM N-(5-Chloro-2-hydroxyphenyl)-N′-[2-chloro-5-
(trifluoromethyl) phenyl]urea (NS-1738). Single-channel recordings were
performed in the cell-attached patch configuration at −70 mV membrane
potential with100 µM ACh and 10 µM NS-1738 and in the absence or
presence of Aβ. (A) Representative channel currents are shown for each
condition. (B) Decrease of mean open and burst durations by Aβ. Each value
corresponds to the mean ± SD of n different recordings (shown in the bars).
The open and burst durations for each recording were obtained from the
corresponding histograms and correspond to the slowest open components
∗p < 0.05, ∗∗∗∗p < 0.0001.
involved in Aβ toxicity as well as crosstalk between Aβ- and
α7-triggered signaling pathways (see review in Buckingham
et al., 2009; Dougherty et al., 2003; Parri et al., 2011). However,
the molecular mechanism by which Aβ affects α7 ionotropic
activity is not well understood and has been explored mainly
at the macroscopic current level. Thus, we took advantage of
two different approaches to decipher the molecular basis of
the direct actions of oligomeric Aβ at α7. Our spectroscopic
results revealed that α7 adopts distinct stable conformations
depending on the Aβ concentration range, and our single-
channel recordings revealed that Aβ triggers α7 channel openings
at low concentrations (picomolar to low nanomolar range)
whereas at high concentrations (nanomolar to low micromolar
range) it decreases the duration of ACh-elicited activation
episodes. Both results fully support the idea that Aβ can act
as an agonist and a negative modulator of α7 at different,
physiologically attainable, concentrations.
One of the main concerns of working with Aβ is related
to the standardization of the oligomeric preparations since
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aggregation is a dynamic and complex process, which is
highly sensitive to preparation, experimental and analyzing
conditions (Bitan et al., 2005; Buckingham et al., 2009; Hayden
and Teplow, 2013; Watt et al., 2013). Thus, preparations are
usually heterogenous sincemany types of soluble species co-exist.
However, this scenario mimics the physiological/pathological
situations where different oligomeric species and fibrils co-exist
in a dynamic equilibrium (Walsh et al., 2000; Shankar et al., 2008;
Noguchi et al., 2009; Santos et al., 2012; Esparza et al., 2016).
Nevertheless, the results obtained with different Aβ oligomer
preparations have yielded rather consistent results (Palop and
Mucke, 2010). In particular, the effects exerted by our Aβ
preparations, which are compatible with a heterogeneous array
of oligomers and the absence of fibrils, are in general agreement
with previous reported effects of oligomeric preparations on α7
(Liu et al., 2001; Dineley et al., 2002; Khan et al., 2010; Tong et al.,
2011).
α7 ionotropic activity is characterized by very brief,
sub-millisecond opening events and rapid desensitization
(Bouzat et al., 2008; Corradi and Bouzat, 2016).We found that Aβ
is capable of eliciting α7 activity either in the absence or presence
of the type II PAM PNU-120596. In both conditions, activation
by Aβ was favored at 100 pM or low nanomolar concentrations
and was not detected at micromolar concentrations, in close
agreement with macroscopic recordings of α7 expressed in
oocytes (Dineley et al., 2002, 2015). Channel activity elicited
by Aβ was significantly reduced with respect to that elicited by
ACh in terms of the number of active patches and frequency of
opening events. However, once opened, the mean open duration,
cluster architecture and mean cluster duration were similar to
those of ACh-elicited channel activity.
Conformational changes of α7 driven by the sole presence
of Aβ at a low concentration were sensed by CrV. At
100 pM, oligomeric Aβ drove α7 conformation towards that
of desensitized receptors but the subsequent addition of Carb
allowed further conformational changes. Although this method
senses conformations under equilibrium and cannot provide
information about CrV KD for open channels, the fact that in the
presence of Aβ α7 is still responsive to Carb is compatible with
the induction of both active and desensitized states. Nevertheless,
the conformation of α7 in the presence of low Aβ and high Carb
concentrations is different to that of the desensitized state (high
Carb alone) as sensed by CrV, thus indicating the induction of a
novel conformational state.
The enhancement of α7 activity as a protective role
in AD and for the treatment of cognitive and memory
impairment associated to neurological disorders appears to be
well established (Inestrosa et al., 2013; Lendvai et al., 2013;
Wallace and Bertrand, 2013; Uteshev, 2014; Dineley et al.,
2015; Corradi and Bouzat, 2016; Yang et al., 2017). Also, a
protective, physiological role has been proposed for soluble
Aβ at low concentrations in healthy individuals (Giuffrida
et al., 2009; Puzzo et al., 2015). Thus, the capability of low
concentration Aβ preparations to activate α7 could be related to
beneficial physiological effects. However, it would be expected
that long-term exposure of an activator would lead to receptor
desensitization.
Several reports have shown that high concentrations of Aβ
have an inhibitory effect on the amplitude of α7-activated
macroscopic currents as well as on signaling pathways (Dineley
et al., 2002; Parri et al., 2011). In close agreement, we found
that in the presence of PAMs the mean duration of activation
episodes (clusters or bursts), which arise from a single receptor
molecule, as well as the open channel lifetime are significantly
reduced by high concentrations of oligomeric Aβ. There was
also a trend of reduced mean durations in the absence of PAMs,
but values were not statistically significantly different to the
control. However, due to the very brief durations, which are
close to the time-resolution limit of our system, such reduction
may be underestimated. From a mechanistic point of view, the
decreased duration of activation episodes and openings may
be compatible with increased desensitization and/or channel
block. We can discard fast open-channel blockade since brief
closings corresponding to blocked openings (flickering) were not
detected. However, enhanced desensitization and slow channel
block processes are difficult to distinguish by electrophysiological
techniques (Arias et al., 2009; Bouzat and Sine, 2018). CrV
experiments showed that at high Aβ concentrations α7 adopts
a conformational state which is not different to the resting state
in terms of CrV KD values and from this state α7 is not further
reactive to Carb. In agreement with these observations, it was
shown for the muscle nAChR that the channel blocker QX-314
does not change the CrV KD value of the resting state and
that this value remains constant even in the presence of Carb
(Fabiani et al., 2018). Thus, we can infer that oligomeric Aβ at
high concentrations behave as a slow channel blocker of α7. The
reduced α7 activity in the presence of Aβ may contribute to the
cholinergic signaling deficit and thus may be involved in the
initiation and development of AD.
The combined action of PAMs and Aβ suggests that
α7 potentiation by PAMs would be probably lower than expected
in AD patients. By macroscopic current recordings it has been
shown that Aβ1–42 inhibits α4β2 and α2β2 receptors and this
inhibition is prevented in the presence of a PAM (Pandya and
Yakel, 2011). These results are not in full disagreement with
ours because, though reduced, we still detected potentiation.
The characterization of the influence of Aβ on α7 potentiation
contributes to a better extrapolation of the molecular effects of
PAMs to their potential therapeutic effects.
A collateral but still important result of our study is the
demonstration of different CrV binding profiles between α7 and
muscle nAChRs. In the muscle nAChR, the CrV affinity for
the desensitized state is greater than for the resting state
whereas in α7 it is the other way around. CrV binds to
luminal non-competitive antagonist sites which are localized in
the channel vestibule (Lurtz and Pedersen, 1999). Our results
showed that the conformation of this region is similar for both
receptors in the resting state, but it is different in the desensitized
state. Thus, the structural arrangements induced by prolonged
exposure to Carb are different between muscle and α7 nAChRs.
Overall, the use of a conformational probe has proved to be useful
for revealing receptor subtype specific structural arrangements
associated with functional states and opens doors to further
studies in this respect.
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The binding site of Aβ remains undefined. Computer
docking studies suggested that Aβ may interact with α7 at
agonist binding-site interfaces (Espinoza-Fonseca, 2004) and the
conserved tyrosine 188 at Loop C of the agonist binding site was
proposed to be involved in α7 activation by Aβ (Tong et al.,
2011). On the other hand, the transmembrane cavity, a binding
site of different allosteric ligands in the Cys-loop receptor family
(Gill et al., 2011; Sauguet et al., 2015; Corradi and Bouzat, 2016),
was proposed to be involved in the noncompetitive block of Aβ
on α4β2 (Pandya and Yakel, 2011). Our spectroscopic results
demonstrating that in the presence of low Aβ concentrations
α7 is still reactive to Carb suggest that Aβ does not occupy
orthosteric agonist binding sites and, in consequence, activation
may be mediated by allosteric sites. Allosteric activation of
α7 through a transmembrane site has been shown for 4BP-
TQS. However, the activity profile is strikingly different to
that of ACh, which is not the case of Aβ (Gill et al., 2011;
Lasala et al., 2018). Alternatively, Aβ may not occupy the five
orthosteric agonist sites but may still be able to induce activation;
the remaining sites, subsequently occupied by Carb, may favor
activation and desensitization. This possibility is in line with our
previous reports showing that occupancy of only one of the five
ACh-binding sites is required for α7 activation (Andersen et al.,
2013). At high concentrations, Aβ may probably inhibit α7 by
acting through an allosteric site, different from that of CrV since
it does not interfere with its binding. Dual actions as low-efficacy
agonists and channel blockers have been described for several
compounds acting at different sites of nAChRs (reviewed in
Bouzat and Mukhtasimova, 2018; Bouzat and Sine, 2018).
Overall, our study provides information from a molecular
perspective to understand Aβ complex actions at the higher
cellular level.
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